Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade B 94.51 2.35% 2.17
BMRN closed up 2.35 percent on Wednesday, December 12, 2018, on 1.12 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical BMRN trend table...

Date Alert Name Type % Chg
Dec 12 20 DMA Resistance Bearish 0.00%
Dec 12 50 DMA Resistance Bearish 0.00%
Dec 12 Crossed Above 200 DMA Bullish 0.00%
Dec 12 Pocket Pivot Bullish Swing Setup 0.00%
Dec 11 20 DMA Resistance Bearish 2.35%
Dec 11 Fell Below 200 DMA Bearish 2.35%
Dec 11 180 Bearish Setup Bearish Swing Setup 2.35%
Dec 10 MACD Bearish Signal Line Cross Bearish 0.72%
Dec 10 Crossed Above 200 DMA Bullish 0.72%
Dec 7 Fell Below 200 DMA Bearish 1.95%

Older signals for BMRN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Is BMRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 106.74
52 Week Low 75.81
Average Volume 1,098,027
200-Day Moving Average 93.2848
50-Day Moving Average 97.1206
20-Day Moving Average 94.6725
10-Day Moving Average 95.179
Average True Range 3.8568
ADX 10.08
+DI 19.5687
-DI 16.9806
Chandelier Exit (Long, 3 ATRs ) 88.3196
Chandelier Exit (Short, 3 ATRs ) 101.8204
Upper Bollinger Band 98.5593
Lower Bollinger Band 90.7857
Percent B (%b) 0.48
BandWidth 8.211043
MACD Line -0.728
MACD Signal Line -0.6278
MACD Histogram -0.1002
Fundamentals Value
Market Cap 16.56 Billion
Num Shares 175 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -88.33
Price-to-Sales 12.04
Price-to-Book 5.17
PEG Ratio -4.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 101.98
Resistance 3 (R3) 102.19 99.90 100.74
Resistance 2 (R2) 99.90 98.00 99.80 100.32
Resistance 1 (R1) 97.21 96.83 98.56 97.00 99.90
Pivot Point 94.92 94.92 95.60 94.82 94.92
Support 1 (S1) 92.23 93.02 93.58 92.02 89.12
Support 2 (S2) 89.94 91.85 89.84 88.70
Support 3 (S3) 87.25 89.94 88.29
Support 4 (S4) 87.04